The Fund's investment objective is to provide a total return primarily through active investment in a value style biased portfolio of equity and equity related securities of companies worldwide.
Name | % Net Assets |
---|---|
Royal Dutch Shell | 1.0% |
Bristol Myers Squibb | 0.8% |
Roche Holding | 0.7% |
Merck & Co | 0.7% |
AstraZeneca | 0.7% |
Eli Lilly | 0.7% |
GlaxoSmithKline | 0.7% |
Lorillard | 0.7% |
Pfizer | 0.7% |
Lockheed Martin | 0.7% |
Key | % Net Assets |
---|---|
Royal Dutch Shell | 1.0% |
Bristol Myers Squibb | 0.8% |
Roche Holding | 0.7% |
Merck & Co | 0.7% |
Other | 96.8% |
Date | 21-Nov-2024 |
---|---|
NAV | 127.40p |
Currency | GBP |
Change | 0.20p |
% | 0.16% |
YTD change | 11.60p |
YTD % | 10.02% |
Fund Inception | 21/12/2005 |
---|---|
Fund Manager | n/a |
TER | 1.69 (20-Jun-2012) |
Minimum Investment | |
---|---|
Initial | n/a |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 3.25% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research